Program Description

Program Description

The Heart in Diabetes (HiD) conference, entering its sixth year, is a unique medical meeting that brings world-renowned clinical leaders in diabetes, obesity and cardiorenal metabolic diseases together with practicing clinicians to improve the care of patients at a high risk of these comorbidities.  

 

HiD 2022 will be held in Philadelphia, PA Loews Philadelphia Hotel 1200 Market St, Philadelphia, PA 19107 on June 24-26, 2022. This Live-in person conference will also be streamed Live online followed by 90 days on demand.

 

This program is designed to evaluate the clinical science aspects of recent cardiovascular outcome trials (CVOTs) and their impact on the prevention and treatment of diabetes, ASCVD, heart failure, kidney and metabolic diseases. The goal is to develop appropriate comprehensive management plans aligning endocrinologists, cardiologists, nephrologists, and all other interested clinicians in their understanding of the new data’s implications on the clinical management of these very high-risk patients.

 

Upon completion of this meeting, participants should be able to:

 

  • Evaluate the extent of vascular disease in diabetes, obesity, and cardiometabolic syndrome

  • Be able to assess cardiovascular risk in diabetes with imaging and biomarkers with a focus on CAC score

  • Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia as well as hyperglycemia

  • Describe optimal use of technology—especially  CGM—and digital technology and their impact on diabetes and CVD

  • Be able to recognize and manage hypoglycemia and its impact on comorbidities

  • Evaluate stroke and dementia in diabetes

  • Discuss the impact of obesity and diets on fatty liver, the kidney, and the heart

  • Evaluate the evidence supporting the use of GLP1-RAs, SGLT2 inhibitors, nonsteroidal MRAs, and other treatments to reduce CKD, HF, and cardiovascular disease and mortality in patients with T2D

  • Understand new and evolving agents in dyslipidemia treatment and how they can be used to reduce ASCVD

  • Discuss changes in management guidelines and the evolution of DCRM multispecialty management approaches

  • Evaluate the impact on clinical practice of new CVOTs, including those evaluating antihyperglycemic, lipid-lowering, and other medications such as nonsteroidal MRAs and anticoagulation therapies

  • Recognize the impact of diabetes and CVD on the severity of COVID-19

  • Describe the state of heart disease in women

  • Discuss diabetes, CKD, CVD, and HF in diverse populations

Initiative/Goal
  • To develop a platform to address the clinical science of the Heart in Diabetes

  • To identify the implications of state-of-the-art clinical research on cardiovascular, liver, and kidney disease in diabetes

  • To further advance the discussion between Cardiologists, Endocrinologists, Nephrologists, Lipidologists, and other interested clinicians, while developing an ongoing interaction in the management and prevention of heart disease in diabetes and cardiometabolic conditions

Target Audience

This educational initiative is designed for endocrinologists, cardiologists, diabetologists, nephrologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

*As we approach the conference, TMIOA/HiD teams are closely monitoring COVID-19 Guidelines for Philadelphia, PA. Please contact info@tmioa.com if you have any questions or concerns.